212
Views
0
CrossRef citations to date
0
Altmetric
Rheumatology

Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients

ORCID Icon
Pages 1031-1043 | Received 31 Mar 2023, Accepted 14 Jun 2023, Published online: 30 Jun 2023

References

  • Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–2284. doi:10.1016/S0140-6736(18)30830-4.
  • Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251.e19–265.e19. doi:10.1016/j.jaad.2018.06.027.
  • Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi:10.1136/annrheumdis-2020-217159.
  • Coates LC, de Wit M, Buchanan-Hughes A, et al. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence. Rheumatol Ther. 2022;9(3):803–821. doi:10.1007/s40744-022-00443-y.
  • Gottlieb A, Gratacos J, Dikranian A, et al. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatol Int. 2019;39(1):121–130. doi:10.1007/s00296-018-4195-x.
  • Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87. doi:10.1136/annrheumdis-2016-209709.
  • Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897. doi:10.1136/annrheumdis-2017-212687.
  • Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999. doi:10.1136/annrheumdis-2013-204655.
  • Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532. doi:10.1136/annrheumdis-2017-212127.
  • Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3.
  • Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chronic Dis. 2021;12:20406223211037846. doi:10.1177/20406223211037846.
  • Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi:10.3389/fimmu.2020.01894.
  • Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152. doi:10.1056/NEJMoa2102383.
  • Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2.
  • Tarsilla M. Cochrane handbook for systematic reviews of interventions. J Multidiscip Eval. 2010;6(14):142–148. doi:10.56645/jmde.v6i14.284.
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi:10.7326/0003-4819-151-4-200908180-00135.
  • Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
  • Clark J, Glasziou P, Del Mar C, et al. A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol. 2020;121:81–90. doi:10.1016/j.jclinepi.2020.01.008.
  • Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
  • Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48. doi:10.1016/s0140-6736(22)02303-0.
  • McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37. doi:10.1016/s0140-6736(22)02302-9.
  • Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440. doi:10.1016/s0140-6736(19)33161-7.
  • Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311–325. doi:10.1038/s41584-022-00776-6.
  • Bobkov YV, Walker WB III, Cattaneo AM. Altered functional properties of the codling moth orco mutagenized in the intracellular loop-3. Sci Rep. 2021;11(1):1–16. doi:10.1038/s41598-021-83024-3.
  • Rodríguez-Ubreva J, de la Calle-Fabregat C, Li T, et al. Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis. Ann Rheum Dis. 2019;78(11):1505–1516. doi:10.1136/annrheumdis-2019-215355.
  • de la Calle-Fabregat C, Rodríguez-Ubreva J, Ciudad L, et al. The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis. JCI Insight. 2022;7(9):e158783 doi:10.1172/jci.insight.158783.
  • Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4–5):496–502. doi:10.1016/j.autrev.2014.01.050.
  • Vičić M, Kaštelan M, Brajac I, et al. Current concepts of psoriasis immunopathogenesis. IJMS. 2021;22(21):11574. doi:10.3390/ijms222111574.
  • Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33(4):391–399. doi:10.1007/s40259-019-00361-6.
  • Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001. doi:10.1111/bcp.13185.
  • He C, Xue C, Zhu G, et al. Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: a combined and updated meta-analysis. J Clin Pharm Ther. 2021;46(4):895–906. doi:10.1111/jcpt.13416.
  • Coates LC, Orbai AM, Morita A, et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity. BMC Rheumatol. 2018;2:24. doi:10.1186/s41927-018-0030-y.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.